No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SAVAW Cassava Sciences Warrants
- 0.380
- -0.040-9.52%
Close Apr 29 16:00 ET
0.520High0.320Low
0.520High0.320Low583.76KVolume0.380Open0.420Pre Close248.54KTurnover0.00%Turnover Ratio--P/E (Static)0Shares11.02052wk High--P/B0Float Cap0.13052wk Low--Dividend TTM0Shs Float11.020Historical High--Div YieldTTM47.60%Amplitude0.130Historical Low0.425Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
News
Redemption Date Announced for Warrants
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference
No Decline in Cognition Scores in Patients With Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Cassava Sciences, Inc. (NASDAQ:SAVA) Most Popular Amongst Retail Investors Who Own 59% of the Shares, Institutions Hold 31%
Comments
$Cassava Sciences Warrants(SAVAW.US$ how to exercise these warrants?
$Cassava Sciences Warrants(SAVAW.US$ Waiting for the inevitable Friday close manipulation, that's how I set my watch. The SEC seemingly couldn't care less, and emboldens them. 23 mins to go watch them work.
$Cassava Sciences Warrants(SAVAW.US$ New Recent January MDPI Scientific Article with Bullish statement about Simufilam. ’Another important aspect of dementia research is the development of new therapeutic approaches aimed at curing the disease or alleviating its symptoms. Hoau-Yan Wang and colleagues [10] investigated the molecular mechanisms of simufilam, a novel oral drug candidate in phase 3 clinical trials for Alzheimer’s dementia. The authors showed that simufilam reduces Aβ42 binding to...
$Cassava Sciences Warrants(SAVAW.US$ if the SEC had anything on or was looking at $SAVA, they certainly wouldn’t have allowed them to move forward into the releasing of the $SAVAW dividend to investors on record as of 12/22/23? If the SEC thought SAVA was shady, no way they would have allowed that. These shorts/Hedge Funds have been manipulating the stock price with no repercussions for more than 3 years and now warrants. Everyone should document days like these with heavy manipulation and expo...
3
$Cassava Sciences Warrants(SAVAW.US$ Shorts, you are bound to meet a heavier demise than what you have caused for the last 3 years of blatant cheating and fake shares short and now the same with SAVA Warrants. Doing this while Former FBI is on the board will not be unnoticed and punishable. Thieves don't know when to quit and they all get caught because of their greed. SAVA Warrants are already on the Reg Sho List. That manipulation today is not going to slide without consequences like it did i...
1
Read more